STOCK TITAN

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Allurion Technologies (NYSE: ALUR) reported its Q4 and full-year 2024 financial results. Q4 revenue was $5.6 million with full-year revenue reaching $32.1 million. The company faced challenges with Q4 gross profit at $2.5 million (45% margin), down from $6.4 million (78% margin) in Q4 2023.

Key developments include:

  • Resumed sales in France on February 12, 2025
  • Positive topline results from AUDACITY FDA trial
  • Initial data showing promising results combining Allurion Program with low-dose GLP-1s
  • Launch of next-generation Allurion Balloon with smaller capsule size

The company reduced Q4 2024 operating expenses by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges. For 2025, Allurion projects revenue of approximately $30 million and plans to cut operating expenses by roughly 50% compared to 2024.

Allurion Technologies (NYSE: ALUR) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024. I ricavi del quarto trimestre sono stati di 5,6 milioni di dollari, con ricavi annuali che hanno raggiunto i 32,1 milioni di dollari. L'azienda ha affrontato delle sfide, con un profitto lordo nel quarto trimestre di 2,5 milioni di dollari (margine del 45%), in calo rispetto ai 6,4 milioni di dollari (margine del 78%) del quarto trimestre 2023.

Sviluppi chiave includono:

  • Ripresa delle vendite in Francia il 12 febbraio 2025
  • Risultati positivi della fase iniziale del trial AUDACITY FDA
  • Dati iniziali che mostrano risultati promettenti combinando il Programma Allurion con GLP-1 a basso dosaggio
  • Lancio del pallone Allurion di nuova generazione con dimensioni della capsula più piccole

L'azienda ha ridotto le spese operative del quarto trimestre 2024 del 39% rispetto all'anno precedente, portandole a 19,6 milioni di dollari, inclusi 3,8 milioni di dollari in spese di ristrutturazione. Per il 2025, Allurion prevede ricavi di circa 30 milioni di dollari e pianifica di ridurre le spese operative di circa il 50% rispetto al 2024.

Allurion Technologies (NYSE: ALUR) informó sobre sus resultados financieros del cuarto trimestre y del año completo 2024. Los ingresos del cuarto trimestre fueron de 5,6 millones de dólares, con ingresos anuales alcanzando los 32,1 millones de dólares. La compañía enfrentó desafíos, con un beneficio bruto en el cuarto trimestre de 2,5 millones de dólares (margen del 45%), en comparación con los 6,4 millones de dólares (margen del 78%) del cuarto trimestre de 2023.

Los desarrollos clave incluyen:

  • Reanudación de ventas en Francia el 12 de febrero de 2025
  • Resultados positivos de la prueba AUDACITY de la FDA
  • Datos iniciales que muestran resultados prometedores al combinar el Programa Allurion con GLP-1 de baja dosis
  • Lanzamiento del globo Allurion de nueva generación con un tamaño de cápsula más pequeño

La compañía redujo los gastos operativos del cuarto trimestre de 2024 en un 39% interanual a 19,6 millones de dólares, incluidos 3,8 millones de dólares en cargos de reestructuración. Para 2025, Allurion proyecta ingresos de aproximadamente 30 millones de dólares y planea recortar los gastos operativos en aproximadamente un 50% en comparación con 2024.

Allurion Technologies (NYSE: ALUR)는 2024년 4분기 및 연간 재무 결과를 발표했습니다. 4분기 수익은 560만 달러였으며, 연간 수익은 3,210만 달러에 달했습니다. 회사는 4분기 총 이익이 250만 달러(45% 마진)로, 2023년 4분기 640만 달러(78% 마진)에서 감소하는 어려움에 직면했습니다.

주요 발전 사항은 다음과 같습니다:

  • 2025년 2월 12일 프랑스에서 판매 재개
  • AUDACITY FDA 시험의 긍정적인 초기 결과
  • Allurion 프로그램과 저용량 GLP-1을 결합한 유망한 결과를 보여주는 초기 데이터
  • 더 작은 캡슐 크기의 차세대 Allurion 풍선 출시

회사는 2024년 4분기 운영 비용을 전년 대비 39% 줄여 1,960만 달러로, 이 중 380만 달러는 구조 조정 비용이 포함되었습니다. 2025년에는 Allurion이 약 3천만 달러의 수익을 예상하고 2024년 대비 운영 비용을 약 50% 줄일 계획입니다.

Allurion Technologies (NYSE: ALUR) a publié ses résultats financiers pour le quatrième trimestre et l'année complète 2024. Les revenus du quatrième trimestre s'élevaient à 5,6 millions de dollars, tandis que les revenus annuels ont atteint 32,1 millions de dollars. L'entreprise a rencontré des défis, avec un bénéfice brut au quatrième trimestre de 2,5 millions de dollars (marge de 45%), en baisse par rapport à 6,4 millions de dollars (marge de 78%) au quatrième trimestre 2023.

Les développements clés incluent :

  • Reprise des ventes en France le 12 février 2025
  • Résultats positifs de l'essai AUDACITY de la FDA
  • Données initiales montrant des résultats prometteurs en combinant le Programme Allurion avec des GLP-1 à faible dose
  • Lancement du ballon Allurion de nouvelle génération avec une taille de capsule plus petite

L'entreprise a réduit ses dépenses d'exploitation du quatrième trimestre 2024 de 39% par rapport à l'année précédente, atteignant 19,6 millions de dollars, y compris 3,8 millions de dollars de charges de restructuration. Pour 2025, Allurion prévoit des revenus d'environ 30 millions de dollars et prévoit de réduire ses dépenses d'exploitation d'environ 50% par rapport à 2024.

Allurion Technologies (NYSE: ALUR) hat seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 bekannt gegeben. Der Umsatz im vierten Quartal betrug 5,6 Millionen Dollar, während der Jahresumsatz 32,1 Millionen Dollar erreichte. Das Unternehmen sah sich Herausforderungen gegenüber, da der Bruttogewinn im vierten Quartal bei 2,5 Millionen Dollar (45% Marge) lag, im Vergleich zu 6,4 Millionen Dollar (78% Marge) im vierten Quartal 2023.

Wichtige Entwicklungen umfassen:

  • Wiederaufnahme der Verkäufe in Frankreich am 12. Februar 2025
  • Positive Ergebnisse aus der AUDACITY FDA-Studie
  • Erste Daten, die vielversprechende Ergebnisse bei der Kombination des Allurion-Programms mit niedrig dosierten GLP-1s zeigen
  • Markteinführung des nächsten Generation Allurion Ballons mit kleinerer Kapselgröße

Das Unternehmen reduzierte die Betriebskosten im vierten Quartal 2024 im Vergleich zum Vorjahr um 39% auf 19,6 Millionen Dollar, einschließlich 3,8 Millionen Dollar an Umstrukturierungskosten. Für 2025 prognostiziert Allurion einen Umsatz von etwa 30 Millionen Dollar und plant, die Betriebskosten im Vergleich zu 2024 um etwa 50% zu senken.

Positive
  • Positive topline results from AUDACITY FDA trial
  • Resumed sales in France
  • 4% growth in full-year procedure volume
  • 39% reduction in operating expenses
  • Launch of next-generation balloon with improved features
  • Financing secured through potential 2026 FDA approval
Negative
  • Q4 revenue declined from $8.2M to $5.6M year-over-year
  • Q4 gross margin dropped from 78% to 45% year-over-year
  • 2025 revenue guidance of $30M indicates decline from 2024's $32.1M
  • Operating loss of $17.1M in Q4 2024
  • Lower production volumes affecting manufacturing costs

Insights

Allurion's Q4 and FY2024 results paint a picture of a company implementing significant restructuring amid revenue challenges. Q4 revenue declined 32% year-over-year to $5.6 million, with full-year revenue at $32.1 million. The most concerning metric is the Q4 gross margin compression to 45% from 78% a year earlier, though full-year margin was healthier at 67%.

The company attributed revenue weakness to a temporary sales suspension in France (now resolved) and macroeconomic headwinds affecting reorder rates. Despite these challenges, procedure volume grew 4% for the year, exceeding guidance and suggesting underlying demand remains intact.

On the expense front, Allurion has made dramatic cuts, reducing Q4 operating expenses by 39% year-over-year to $19.6 million (including $3.8 million in restructuring charges). Management plans to slash 2025 operating expenses by approximately 50% compared to 2024 levels, signaling a fundamental reset focused on capital efficiency.

With $15.4 million cash at year-end and substantially reduced burn rate, Allurion believes it has sufficient runway through potential FDA approval in 2026. The 2025 revenue guidance of approximately $30 million represents a slight year-over-year decline despite resuming France sales, indicating continued near-term pressure as the company repositions for potential profitability.

Allurion's strategic pivot to position its gastric balloon as complementary to GLP-1 medications represents an intelligent adaptation to evolving weight management dynamics. Their initial data showing optimization of muscle mass and improved GLP-1 adherence through combination therapy directly addresses two critical limitations of GLP-1 medications: muscle loss and adherence challenges.

The positive topline results from the AUDACITY FDA trial mark a crucial regulatory milestone that could open the substantial U.S. market to Allurion's swallowable balloon system. This non-surgical, non-endoscopic approach would fill a significant treatment gap between pharmaceutical interventions and more invasive bariatric procedures.

Product development continues despite restructuring, with their next-generation balloon featuring a smaller capsule and increased radiopacity - improvements enhancing both patient comfort and clinical monitoring. The company's advancement of R&D while reducing overall expenses demonstrates focused prioritization of high-value initiatives.

The resumption of sales in France represents another positive catalyst that should help stabilize the revenue base in 2025. The 4% growth in procedure volume during 2024 despite organizational challenges suggests the Allurion Program maintains clinical relevance even as GLP-1 medications reshape the weight management landscape.

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

Recent Company Highlights and Outlook

  • Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach
  • Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025
  • Fourth quarter 2024 operating expenses of $19.6 million, a decrease of 39% compared to the same period in the prior year, and included one-time restructuring charges of $3.8 million
  • Full-year 2024 procedure volume growth of 4%, above previously issued guidance, despite the reduction in operating expenses compared to prior year
  • Cleared to resume sales in France on February 12, 2025
  • Positive topline readout for AUDACITY FDA clinical trial, setting stage for submission of pre-market approval (“PMA”) application
  • Recent financings expected to fund business through potential FDA approval of the Allurion Balloon in 2026
  • Advanced R&D pipeline with the launch of next-generation Allurion Balloon with smaller capsule size and increased radiopacity
  • 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024

“In 2024, we restructured and refocused Allurion for the future and have been thrilled with the recent milestones we have achieved,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “The initial results on the combination of the Allurion Program with low-dose GLP-1s, clearance to resume sales in France, and positive topline readout from the AUDACITY trial were all significant moments for our company. Momentum built in the fourth quarter as our new commercial strategy began to take hold, and procedure volume grew most in regions where GLP-1s are relatively mature in the market, suggesting, we believe, that patients are entering the funnel seeking either an alternative or combination approach to weight loss.

“As the first quarter comes to a close, we see further momentum building and a 2025 that is rich in potential catalysts,” continued Dr. Gaur. “With our recent financings complete, we believe we have a cash runway through becoming EBITDA positive and receiving FDA approval of the Allurion Balloon. And, as we initiate prospective studies on our combination approach, advance our PMA application through the FDA, and set the stage for profitability, I have no doubt we are building out an exciting future for Allurion.”

Fourth Quarter Financial Results

Total revenue for the quarter ended December 31, 2024 was $5.6 million, compared to $8.2 million for the same period in 2023. The year-over-year decrease in revenue was primarily due to the temporary suspension of sales in France and macroeconomic headwinds in certain markets leading to lower re-order rates.

Gross profit for the fourth quarter ended December 31, 2024 was $2.5 million, or 45% of revenue, compared to $6.4 million, or 78% of revenue, for the same period in 2023. Gross profit for the fourth quarter ended December 31, 2024 was negatively impacted by the reduction in revenue in the period and lower production volumes, which resulted in less manufacturing labor and overhead being absorbed into inventory costs. We also recorded an adjustment of excess and obsolete scrap related to inventory on hand with a shelf life of less than six months, which was primarily due to the reduction in revenue and temporary suspension of sales in France.

For the full-year ended December 31, 2024, gross profit was $21.5 million, or 67% of revenue. Gross profit margin is expected to expand in 2025 with inventory levels normalizing and sales resuming in France.

Sales and marketing expenses for the fourth quarter of 2024 were $7.9 million, compared to $10.7 million for the same period in 2023, and included $3.1 million of restructuring costs. The reduction in expense was primarily driven by increased operating efficiency and the restructuring initiatives implemented during the fourth quarter of 2024, which re-focused spend on more efficient channels.

R&D expenses for the fourth quarter of 2024 were $4.1 million, compared to $6.1 million for the same period in 2023, and included $0.3 million of restructuring costs. The reduction was primarily driven by reduced costs related to the AUDACITY trial and restructuring initiatives implemented during the fourth quarter.

G&A expenses for the fourth quarter of 2024 were $7.7 million, compared to $15.4 million for the same period in 2023, and included restructuring and financing costs of $1.1 million. The reduction was primarily driven by decreases in bad debt expense and in stock-based compensation and the restructuring initiatives implemented during the fourth quarter.

Loss from operations for the fourth quarter was $17.1 million, compared to $25.7 million for the same period in 2023, and included $4.6 million of restructuring and financing costs. The reduction was driven by restructuring initiatives implemented during the fourth quarter.

Cash balance on December 31, 2024 was $15.4 million.

Conference Call and Webcast Details

Company management will host a conference call to discuss financial results and provide a business update on March 26, 2025 at 8:30 AM ET.

To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion’s Investor Relations website at Allurion - Events & Presentations.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Allurion believes that it has a reasonable basis for each forward-looking statement contained in this press release, Allurion cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which it cannot be certain.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s financial outlook for 2025 and future years, including the anticipated impact of the 2024 restructuring plan on the Company’s operating expenses and its ability to achieve profitability and be EBITDA positive in 2026; the expected impact of resumed sales in France; anticipated procedural volume growth; the Company’s ability, through the implementation of the 2024 restructuring plan, refocused strategy, and use of capital from financings, to increase operational and financial flexibility, position itself to navigate an evolving economic landscape, and extend its financial runway for sustained future growth in 2025 and beyond; ; the Company’s beliefs with respect to the shift in commercial strategy, including with respect to sales and marketing; the outcome of the Company’s PMA seeking FDA approval of the Allurion Balloon following the topline readout of the AUDACITY clinical trial; the performance and market acceptance of products, including VCS and the Coach Iris feature, for patients using different weight loss therapies both outside and within the United States, as well as the Company’s ability to expand these aspects of its business further in 2025; the outcomes of anticipated studies on the combination of GLP-1s with the Allurion Balloon and the impact on demand for our products and services; ; and the market and demand for our products and weight-loss solutions in general, including GLP-1 drugs and elective procedures.

Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program; the timing of, and results from, its clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange;, the Russia and Ukraine war and the Israel-Hamas war on Allurion’s business and financial results; the outcome of any legal proceedings against Allurion; the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion competes; and those factors discussed under the heading “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 13, 2024, its Annual Report on Form 10-K filed with the SEC on March 26, 2024, and other filings with the SEC. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that Allurion will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent Allurion’s views as of the date of this press release. Allurion anticipates that subsequent events and developments will cause its views to change. However, while Allurion may elect to update these forward-looking statements at some point in the future, Allurion has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing Allurion’s views as of any date subsequent to the date of this press release.

 

Consolidated Statements of Operations

(dollars in thousands, except per share amounts)(unaudited)

 

 

 

Three Months Ended
December 31,

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

 

$

5,591

 

 

$

8,235

 

 

$

32,110

 

 

$

53,467

 

Cost of revenue

 

 

3,058

 

 

 

1,805

 

 

 

10,607

 

 

 

11,970

 

Gross profit

 

 

2,533

 

 

 

6,430

 

 

 

21,503

 

 

 

41,497

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

7,873

 

 

 

10,730

 

 

 

25,933

 

 

 

46,857

 

Research and development

 

 

4,122

 

 

 

6,071

 

 

 

17,369

 

 

 

27,694

 

General and administrative

 

 

7,653

 

 

 

15,367

 

 

 

28,399

 

 

 

46,024

 

Total operating expenses:

 

 

19,648

 

 

 

32,168

 

 

 

71,701

 

 

 

120,575

 

Loss from operations

 

 

(17,115

)

 

 

(25,738

)

 

 

(50,198

)

 

 

(79,078

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

 

 

 

(3,235

)

 

 

(2,264

)

 

 

(10,566

)

Changes in fair value of warrants

 

 

2,814

 

 

 

6,175

 

 

 

17,024

 

 

 

8,364

 

Changes in fair value of debt

 

 

(1,330

)

 

 

 

 

 

8,690

 

 

 

(3,751

)

Changes in fair value of Revenue Interest Financing and
PIPE Conversion Option

 

 

(4,713

)

 

 

(152

)

 

 

(14,321

)

 

 

(2,192

)

Changes in fair value of earn-out liabilities

 

 

760

 

 

 

4,720

 

 

 

22,900

 

 

 

29,050

 

Termination of convertible note side letters

 

 

 

 

 

 

 

 

 

 

 

(17,598

)

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

(8,713

)

 

 

(3,929

)

Other income (expense), net

 

 

(477

)

 

 

(776

)

 

 

1,452

 

 

 

(643

)

Total other income (expense):

 

 

(2,946

)

 

 

6,732

 

 

 

24,768

 

 

 

(1,265

)

Loss before income taxes

 

 

(20,061

)

 

 

(19,006

)

 

 

(25,430

)

 

 

(80,343

)

Provision for income taxes

 

 

(508

)

 

 

(174

)

 

 

(718

)

 

 

(264

)

Net loss

 

 

(20,569

)

 

 

(19,180

)

 

 

(26,148

)

 

 

(80,607

)

Cumulative undeclared preferred dividends

 

 

 

 

 

 

 

 

 

 

 

(1,697

)

Net loss attributable to common shareholders

 

$

(20,569

)

 

$

(19,180

)

 

$

(26,148

)

 

$

(82,304

)

Net loss per share

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(7.95

)

 

$

(10.09

)

 

$

(11.64

)

 

$

(57.83

)

Weighted-average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

2,588,912

 

 

 

1,900,816

 

 

 

2,247,164

 

 

 

1,423,275

 

 

Consolidated Balance Sheets

(dollars in thousands)(unaudited)

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

15,379

 

 

$

38,037

 

Accounts receivable, net of allowance of doubtful accounts of $6,701 and
$12,671, respectively

 

 

7,134

 

 

 

18,194

 

Inventory, net

 

 

3,400

 

 

 

6,171

 

Prepaid expenses and other current assets

 

 

1,243

 

 

 

2,414

 

Total current assets

 

 

27,156

 

 

 

64,816

 

Property and equipment, net

 

 

2,469

 

 

 

3,381

 

Right-of-use asset

 

 

2,079

 

 

 

3,010

 

Other long-term assets

 

 

1,109

 

 

 

505

 

Total assets

 

$

32,813

 

 

$

71,712

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

6,572

 

 

$

10,379

 

Current portion of term loan

 

 

 

 

 

38,643

 

Current portion of lease liabilities

 

 

869

 

 

 

908

 

Accrued expenses and other current liabilities

 

 

11,422

 

 

 

15,495

 

Total current liabilities

 

 

18,863

 

 

 

65,425

 

Convertible notes payable

 

 

35,710

 

 

 

 

Warrant liabilities

 

 

4,567

 

 

 

6,765

 

Revenue Interest Financing liability

 

 

49,200

 

 

 

36,200

 

Earn-out liabilities

 

 

1,090

 

 

 

23,990

 

Lease liabilities, net of current portion

 

 

1,344

 

 

 

2,306

 

Other liabilities

 

 

17

 

 

 

7,513

 

Total liabilities

 

 

110,791

 

 

 

142,199

 

Commitments and Contingencies

 

 

 

 

 

 

Stockholders’ deficit:

 

 

 

 

 

 

Preferred stock, $0.0001 par value — 100,000,000 shares authorized as of
December 31, 2024; and no shares issued and outstanding as of December
31, 2024 and December 31, 2023

 

 

 

 

 

 

Common stock, $0.0001 par value - 1,000,000,000 shares authorized as of
December 31, 2024; 2,710,607 and 1,907,529 shares issued and outstanding
as of December 31, 2024 and 2023, respectively

 

3

 

 

 

2

 

Additional paid-in capital

 

 

152,596

 

 

 

143,010

 

Accumulated other comprehensive income (loss)

 

 

8,370

 

 

 

(700

)

Accumulated deficit

 

 

(238,947

)

 

 

(212,799

)

Total stockholders’ deficit

 

 

(77,978

)

 

 

(70,487

)

Total liabilities and stockholders’ deficit

 

$

32,813

 

 

$

71,712

 

 

Investor / Media Contact

investors@allurion.com

Source: Allurion Technologies, Inc.

FAQ

What were Allurion's (ALUR) Q4 2024 financial results?

Q4 2024 revenue was $5.6 million with gross profit of $2.5 million (45% margin), and operating expenses of $19.6 million including $3.8 million in restructuring charges.

When will Allurion (ALUR) resume sales in France?

Allurion received clearance to resume sales in France on February 12, 2025.

What is Allurion's (ALUR) revenue guidance for 2025?

Allurion projects revenue of approximately $30 million for 2025.

What was the outcome of Allurion's (ALUR) AUDACITY FDA trial?

The AUDACITY FDA trial reported positive topline results, setting the stage for pre-market approval (PMA) application.

When does Allurion (ALUR) expect potential FDA approval for its balloon?

Allurion expects potential FDA approval of the Allurion Balloon in 2026.
ALLURION TECHNOLOGIES INC

NYSE:ALUR

ALUR Rankings

ALUR Latest News

ALUR Stock Data

19.50M
5.40M
13.85%
22.25%
2.11%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NATICK